603718 logo

Shanghai Hile Bio-Technology XSSC:603718 Stock Report

Last Price

CN¥8.23

Market Cap

CN¥5.4b

7D

2.9%

1Y

-20.3%

Updated

30 Apr, 2024

Data

Company Financials

Shanghai Hile Bio-Technology Co., Ltd.

XSSC:603718 Stock Report

Market Cap: CN¥5.4b

603718 Stock Overview

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China.

603718 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends2/6

Shanghai Hile Bio-Technology Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Hile Bio-Technology
Historical stock prices
Current Share PriceCN¥8.23
52 Week HighCN¥11.87
52 Week LowCN¥6.00
Beta1.05
1 Month Change-11.79%
3 Month Change1.23%
1 Year Change-20.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-25.45%

Recent News & Updates

Recent updates

Shareholder Returns

603718CN PharmaceuticalsCN Market
7D2.9%6.1%4.4%
1Y-20.3%-11.9%-12.6%

Return vs Industry: 603718 underperformed the CN Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 603718 underperformed the CN Market which returned -12.6% over the past year.

Price Volatility

Is 603718's price volatile compared to industry and market?
603718 volatility
603718 Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 603718 has not had significant price volatility in the past 3 months.

Volatility Over Time: 603718's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981491James Chenwww.hile-bio.com

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; and inactivated vaccine for streptococcus suis. It also provides inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease, and avian infectious bronchitis combined live vaccines.

Shanghai Hile Bio-Technology Co., Ltd. Fundamentals Summary

How do Shanghai Hile Bio-Technology's earnings and revenue compare to its market cap?
603718 fundamental statistics
Market capCN¥5.41b
Earnings (TTM)CN¥44.92m
Revenue (TTM)CN¥239.79m

120.5x

P/E Ratio

22.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603718 income statement (TTM)
RevenueCN¥239.79m
Cost of RevenueCN¥128.26m
Gross ProfitCN¥111.53m
Other ExpensesCN¥66.62m
EarningsCN¥44.92m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.068
Gross Margin46.51%
Net Profit Margin18.73%
Debt/Equity Ratio6.0%

How did 603718 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

22%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.